Drug intelligence / Profile preview

Yuping Linglu Fang

Development stage: Preclinical
Lead developer: Affiliated Hospital of Shanxi University of Chinese Medicine

Overview

Yuping Linglu Fang is a Traditional Chinese Medicine (TCM) compound. Its specific formulation includes Milkvetch Root, Largehead Atractylodes Rh, Radix Saposhnikoviae Divaricatae, Ganoderma, and Pyrolae Herba. It is currently being investigated for its potential to prevent Coronavirus myocarditis by regulating the Th17/Treg immune balance.

Beyond the preview

Go deeper on Yuping Linglu Fang.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yuping Linglu Fang.

Explore the full profile